Monoclonal antibody-induced cytokine-release syndrome
Authors:
- Peter J BugelskiPBPeter J Bugelski
- Ram AchuthanandamRARam Achuthanandam
- Renold J CapocasaleRCRenold J Capocasale
- George TreacyGTGeorge Treacy
- Esther Bouman-ThioEBEsther Bouman-Thio
- 1 September 2009
- journal article
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 5 (5) , 499-521
Abstract
Monoclonal antibodies (mAbs) are widely used in anti-inflammatory and tumor therapy. Although effective, mAbs can cause a variety of adverse effects. An important toxicity seen with a few mAbs is cytokine-release syndrome (CRS). These mAbs include: alemtuzumab, muromonab-CD3, rituximab, tosituzumab, CP-870,893, LO-CD2a/BTI-322 and TGN1412. By contrast, over 30 mAbs used clinically are not associated with CRS. In this review, the clinical aspects of CRS, the mAbs associated with CRS, the cytokines involved and putative mechanisms mediating cytokine release will be discussed. This will be followed by a discussion of the poor predictive value of studies in animals and the prospects for creating in vitro screens. Finally, approaches to decreasing the probability of CRS, decreasing the severity or treating CRS, should it occur, will be described.Keywords
This publication has 171 references indexed in Scilit:
- Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-GalactoseNew England Journal of Medicine, 2008
- Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage–derived cytokinesJournal of Allergy and Clinical Immunology, 2008
- Complement-targeted therapeuticsNature Biotechnology, 2007
- Successful management of infusion reaction accompanying the start of cetuximab therapySupportive Care in Cancer, 2006
- Loss of Siglec expression on T lymphocytes during human evolutionProceedings of the National Academy of Sciences, 2006
- Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancerBritish Journal of Cancer, 2006
- Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeysTransplant Immunology, 2003
- Antiproliferative, antiangiogenic and proapoptotic activity of h‐R3: A humanized anti‐EGFR antibodyInternational Journal of Cancer, 2002
- ADMINISTRATION OF OKT3 AS A TWO-HOUR INFUSION ATTENUATES FIRST-DOSE SIDE EFFECTS1Transplantation, 1997
- A RANDOMIZED TRIAL COMPARING SAFETY AND EFFICACY OF OKT3 AND A MONOCLONAL ANTI-INTERLEUKIN-2 RECEPTOR ANTIBODY (BT563) IN THE PREVENTION OF ACUTE REJECTION AFTER HEART TRANSPLANTATIONTransplantation, 1996